Sam Brusco, Associate Editor06.22.22
BioSig Technologies began a new evaluation agreement with Cleveland Clinic for its PURE EP system. The company aims to advance electrophysiology workflow with greater intracardiac signal fidelity through the PURE EP signal processing platform.
Cleveland Clinic will evaluate the PURE EP system for 60 days. BioSig has recently restructured its clinical support and installation teams to streamline the journey from product evaluation to adoption.
The agreement is the first since the company inducted a new commercialization team.
“We are excited to include Cleveland Clinic as an evaluation center for the PURE EP System. We look forward to working alongside their physicians to demonstrate the superior signal quality that can be achieved on even the most difficult arrhythmias,” Gray Fleming, BioSig’s chief commercialization officer told the press.
To date over 75 physicians have completed over 2,500 cases using PURE EP, and the company is in a national commercial launch.
Cleveland Clinic will evaluate the PURE EP system for 60 days. BioSig has recently restructured its clinical support and installation teams to streamline the journey from product evaluation to adoption.
The agreement is the first since the company inducted a new commercialization team.
“We are excited to include Cleveland Clinic as an evaluation center for the PURE EP System. We look forward to working alongside their physicians to demonstrate the superior signal quality that can be achieved on even the most difficult arrhythmias,” Gray Fleming, BioSig’s chief commercialization officer told the press.
To date over 75 physicians have completed over 2,500 cases using PURE EP, and the company is in a national commercial launch.